NAD+ is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-13. Numbers and descriptions here follow the published literature rather than marketing material.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
Identity and purity of NMN are commonly assessed by liquid chromatography with ultraviolet detection or mass spectrometry. High-performance liquid chromatography can separate related impurities such as nicotinamide, nicotinamide riboside, and NAD+ depending on the method. Mass spectrometry provides molecular mass confirmation, while nuclear magnetic resonance spectroscopy helps establish structure and anomeric form. Quantitative assays often use calibration curves and, in biological samples, stable isotope-labeled internal standards. Method validation addresses specificity, linearity, accuracy, precision, and limits of detection.
Quality control for NMN materials typically includes appearance, assay, impurity profile, residual solvents, heavy metals, and microbial limits. A certificate of analysis summarizes specified tests, but the underlying methods and laboratory accreditation matter. Regulatory treatment varies by country; NMN is sold as a dietary supplement in some markets, while other jurisdictions restrict its use in foods or classify it differently. Independent verification can reduce risks of mislabeling or substitution. Questions remain about how product purity, storage history, and formulation affect delivered dose in humans.
Solid NMN is a polar, water-soluble nucleotide that can absorb moisture from air. Its phosphate ester is susceptible to hydrolysis, and degradation is faster in aqueous solution, under strongly acidic or alkaline conditions, and at elevated temperatures. For laboratory and commercial handling, the solid is typically kept desiccated, protected from light, and stored frozen. Repeated freeze-thaw cycles can introduce moisture and accelerate breakdown. Stability data for specific formulations should be generated rather than assumed from the parent compound.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C11H15N2O8P | Identifies the atoms in the nucleotide |
| Molar mass | 334.22 g/mol | Calculated from the molecular formula |
| Appearance | White to off-white powder | Typical for purified solid material |
| Solubility | Water-soluble | Polar nucleotide; less soluble in nonpolar solvents |
| Common synonyms | Nicotinamide mononucleotide; beta-NMN | beta-NMN refers to the common anomeric form |
== Education and professional development == The HGSA oversees professional training and certification in the fields of Diagnostic Genomics and Genetic Counseling. Two Boards of Censors oversee training in these two respective fields. The HGSA partners with the Royal College of Pathologists of Australasia to train senior diagnostic genomicists to become Fellows of the Faculty of Science. The Australasian Association of Clinical Geneticists (AACG), a Special Interest Group of the HGSA, has direct ties with the Royal Australasian College of Physicians (RACP), which is the body that oversees training and accreditation in clinical genetics in Australasia. The AACG advises the RACP on curricula and training requirements. In addition, members of the AACG supervise the clinical training of RACP trainees in clinical genetics. The AACG also oversees a lecture series for clinical genetics trainees. The HGSA hosts a large number of educational events throughout the year to help members undertake continuing professional development. In addition to the Society's Annual Scientific Meeting, members have access to a large number of webinars that are broadcast across Australia and New Zealand. Furthermore, each Branch holds face-to-face educational activities, such as lectures and symposia, for local members.
Since the tight control of enzyme activity is essential for homeostasis, any malfunction (mutation, overproduction, underproduction or deletion) of a single critical enzyme can lead to a genetic disease. The malfunction of just one type of enzyme out of the thousands of types present in the human body can be fatal. An example of a fatal genetic disease due to enzyme insufficiency is Tay–Sachs disease, in which patients lack the enzyme hexosaminidase. One example of enzyme deficiency is the most common type of phenylketonuria. Many different single amino acid mutations in the enzyme phenylalanine hydroxylase, which catalyzes the first step in the degradation of phenylalanine, result in build-up of phenylalanine and related products. Some mutations are in the active site, directly disrupting binding and catalysis, but many are far from the active site and reduce activity by destabilising the protein structure, or affecting correct oligomerisation. This can lead to intellectual disability if the disease is untreated. Another example is pseudocholinesterase deficiency, in which the body's ability to break down choline ester drugs is impaired. Oral administration of enzymes can be used to treat some functional enzyme deficiencies, such as pancreatic insufficiency and lactose intolerance. Another way enzyme malfunctions can cause disease comes from germline mutations in genes coding for DNA repair enzymes. Defects in these enzymes cause cancer because cells are less able to repair mutations in their genomes.
Treatment can be with oral therapy such as pentoxifylline (an anti-fibrotic phosphodiesterase inhibitor). Pentoxifylline lowers inflammation by blocking transforming growth factor beta 1 (TGF-β1), which interferes with the production of collagen type I. Pain management in the active phase of the disease can be provided by non-steroidal anti-inflammatory drugs (NSAID). One of the main symptoms of active Peyronie's disease is pain with or without erection. Pain is often distressing to patients and may compromise sexual function. Pain level should be periodically checked to measure treatment efficacy. Not recommended oral therapies include Acetyl-L-carnitine and vitamin E .
== Prevention by food == Scurvy can be prevented by a diet that includes uncooked vitamin C-rich foods providing as little as 10 mg of vitamin C per day. Common examples in typical serving amounts include kiwifruit, grapefruit, strawberries, bell peppers, and citrus fruits. About five servings per day of fresh fruits and vegetables supply enough vitamin C to exceed the scurvy threshold by 10-fold. Nutritional supplements that provide ascorbic acid well above what is required to prevent scurvy may cause adverse health effects. Uncooked fresh meat from animals, notably internal organs such as liver, contains enough vitamin C to prevent scurvy, and even partly treat it. Scott's 1902 Antarctic expedition used fresh seal meat and increased allowance of bottled fruits which reportedly led to complete recovery from incipient scurvy in less than two weeks.
Sources: en.wikipedia.org
Physical activity, specifically resistance training, stimulates growth of bones by increasing both bone density and strength. Studies have shown a positive correlation between the adaptations of resistance training and bone density. While nutritional and pharmacological approaches may also improve bone health, the strength and balance adaptations from resistance training are a substantial added benefit. Weight-bearing exercise may assist in osteoblast (bone-forming cells) formation and help to increase bone mineral content. High-impact sports, which involve quick changes in direction, jumping, and running, are particularly effective with stimulating bone growth in the youth. Sports such as soccer, basketball, and tennis have shown to have positive effects on bone mineral density as well as bone mineral content in teenagers. Engaging in physical activity during childhood years, particularly in these high-impact osteogenic sports, can help to positively influence bone mineral density in adulthood. Children and adolescents who participate in regular physical activity will place the groundwork for bone health later in life, reducing the risk of bone-related conditions such as osteoporosis.
A synthetic element is a known chemical element that does not occur naturally on Earth: it has been created by human manipulation of fundamental particles in a nuclear reactor, a particle accelerator, or the explosion of an atomic bomb; thus, it is called "synthetic", "artificial", or "man-made". The synthetic elements are those with atomic numbers 95–118, as shown in purple on the accompanying periodic table: these 24 elements were first created between 1944 and 2010. The mechanism for the creation of a synthetic element is to force additional protons into the nucleus of an element with an atomic number lower than 95. All known (see: Island of stability) synthetic elements are unstable, but they decay at widely varying rates; the half-lives of their longest-lived isotopes range from microseconds to millions of years. Six more elements that were first created artificially are strictly speaking not synthetic because they were later found in nature in trace quantities: technetium (43Tc), promethium (61Pm), astatine (85At), neptunium (93Np), plutonium (94Pu), and curium (96Cm); although they are sometimes classified as synthetic alongside exclusively artificial elements. The first, technetium, was created in 1937. Plutonium, first synthesized in 1940, is another such element. It is the element with the largest number of protons (atomic number) to occur in nature, but it does so in such tiny quantities that it is far more practical to synthesize it. Plutonium is known mainly for its use in atomic bombs and nuclear reactors.
== History == Lixisenatide is a GLP-1 receptor agonist that was created by Zealand Pharma A/S of Denmark; in 2003 Zealand licensed it to Sanofi which developed the drug. Lixisenatide was approved by the European Commission on 1 February 2013. Sanofi submitted an NDA in the US, which was accepted for review by the US FDA in February 2013 but after discussions with the FDA about the cardiovascular safety data included in the package (starting in 2008, the FDA had required stronger CV safety data for new anti-diabetes drugs, following the controversy around the risks of Avandia) Sanofi decided to withdraw the NDA and wait for the results of a Phase III study that was scheduled to be completed in 2015. Sanofi resubmitted the application which the FDA accepted in September 2015, by which time Sanofi had lost the lead in the field of anti-diabetic drugs to Novo Nordisk. Lixisenatide received FDA approval on 28 July 2016. In 2010, Sanofi extended a license agreement it had with Zealand for lixisenatide to allow Sanofi to combine it with insulin glargine, which was Sanofi's best selling drug at the time, with sales of around €3 billion in 2009. Sanofi planned to start the Phase III trial that year. Sanofi submitted the new drug application in December 2015 for the combination and spent a US$245M priority voucher to gain a faster review, to try to outrace Novo Nordisk’s Xultophy, a similar combination drug of Novo's insulin Tresiba and Novo's GLP-1 agonist Victoza.
=== Carbamic acids === Many substituted carbamic acids (RHNCOOH or RR′NCOOH), can be readily synthesized by bubbling carbon dioxide through solutions of the corresponding amine (RNH2 or RR′NH, respectively) in an appropriate solvent, such as DMSO or supercritical carbon dioxide. These carbamic acids are generally unstable at room temperature, reverting to the parent amine and carbon dioxide.
Carbon fixation produces the three-carbon sugar intermediate, which is then converted into the final carbohydrate products. The simple carbon sugars photosynthesis produces are then used to form other organic compounds, such as the building material cellulose, the precursors for lipid and amino acid biosynthesis, or as a fuel in cellular respiration. The latter occurs not only in plants but also in animals when the carbon and energy from plants is passed through a food chain. The fixation or reduction of carbon dioxide is a process in which carbon dioxide combines with a five-carbon sugar, ribulose 1,5-bisphosphate, to yield two molecules of a three-carbon compound, glycerate 3-phosphate, also known as 3-phosphoglycerate. Glycerate 3-phosphate, in the presence of ATP and NADPH produced during the light-dependent stages, is reduced to glyceraldehyde 3-phosphate. This product is also referred to as 3-phosphoglyceraldehyde (PGAL) or, more generically, as triose phosphate. Most (five out of six molecules) of the glyceraldehyde 3-phosphate produced are used to regenerate ribulose 1,5-bisphosphate so the process can continue. The triose phosphates not thus "recycled" often condense to form hexose phosphates, which ultimately yield sucrose, starch, and cellulose, as well as glucose and fructose. The sugars produced during carbon metabolism yield carbon skeletons that can be used for other metabolic reactions like the production of amino acids and lipids.
Sources: en.wikipedia.org
=== 1980s to 2000s: International Expansion === In 1987, Whirlpool began selling compact washers in India and acquired a majority interest in Inglis of Canada. In 1988, Whirlpool bought a 53% stake in the large-appliance division of Philips N.V., creating a joint venture called Whirlpool International. The purchase made Whirlpool the world's largest manufacturer of major appliances, with annual sales of approximately $6 billion. The remaining 47% stake was purchased from Philips in 1991, completing the acquisition. In 1989, Whirlpool acquired the Roper brand and Bauknecht of Germany. Whirlpool entered the Indian market in the late 1980s as part of its global expansion strategy. It founded a joint venture with the TVS Group and established the first Whirlpool manufacturing facility in Puducherry, where it manufactured washing machines. In 1995, Whirlpool acquired Kelvinator India Limited, marking an entry into the refrigerator market as well. That same year, the company acquired major shares in TVS joint venture, and in 1996, the Kelvinator and TVS acquisitions were merged to create Whirlpool of India Limited. This expanded the company's portfolio on the Indian subcontinent to include washing machines, refrigerators, microwave ovens, and air conditioners. Whirlpool of India Limited is headquartered in Gurgaon, and it owns three manufacturing facilities at Faridabad, Puducherry and Pune. The Pune opened most recently, in 2022. In 1997, the company acquired a majority stake in Embraco, a Brazilian maker of compressors for refrigeration.
== Regulation == IGFBP-3 levels in human serum are, like IGF-1, dependent on growth hormone (GH); for example, serum IGFBP-3 is increased in acromegaly and low in GH-deficient children. However, IGFBP-3 gene expression in human liver is GH-independent. Because it is stabilized in human serum by forming complexes with IGF-1 and ALS, which are both GH-dependent, serum IGFBP-3 also appears regulated by GH. Its production by some non-hepatic tissues may also be directly GH-regulated. Immunoassays for serum IGFBP-3 are often used as part of the diagnosis of childhood GH-deficiency. The most widely studied IGFBP3 polymorphism, at nucleotide-202 in the promoter region, is significantly associated with circulating IGFBP-3 levels, although the mechanism is unclear. In some studies circulating IGFBP-3 also appears to be nutritionally regulated, although this may not be seen at the mRNA level. IGFBP-3 has been identified in human lymph, nipple aspirate, milk, amniotic fluid, follicular fluid, seminal plasma, urine, peritoneal dialysate, synovial fluid, tear fluid, and cerebrospinal fluid, in addition to serum. Many factors increase IGFBP-3 production by cells, including transforming growth factor-β (TGFβ), tumor necrosis factor-α, vitamin D, retinoic acid, IGF-1, and stimuli such as chemotherapy that activate the tumor suppressor p53. Estrogen inhibits IGFBP-3 production, and its tissue levels are lower in estrogen receptor (ER)-positive breast cancers than in ER-negative cancers.
== Football career == He made his debut in 2001 with the Essendon Football Club and proved to be a solid ruckman for a number of years. In 2006, Hille was appointed stand-in captain after Matthew Lloyd suffered a season-ending hamstring injury in round three. He captained his first game in Round 6, 2006. From 2007 to 2012, he held the role of vice-captain of the Essendon Football Club which he shared with Mark McVeigh for the most part. In the Round 17, 2006 clash between Essendon and Brisbane Lions (the first match Essendon won under his captaincy, and since the beginning of April that year), Brisbane ruckman Jamie Charman fell heavily in a contest, seriously injuring his shoulder. The image of David Hille comforting his opponent whilst medical help arrived was often replayed by the football media as a rare example of sportsmanship in such a competitive game. At the 2008 Essendon Best and Fairest, Hille swept the floor by taking the most prestigious award of the night, the 'Best and Fairest'. Hille also came away with the 'Cheersquad award'. Hille suffered a knee injury in the second minute of the Bombers' annual ANZAC Day match against Collingwood in Round 5, 2009. Scans confirmed he had ruptured his anterior cruciate ligament, requiring a full knee construction and ending his season.
=== Alcohol === The removal of ethanol (drinking alcohol) through oxidation by alcohol dehydrogenase in the liver from the human body is limited. Hence the removal of a large concentration of alcohol from blood may follow zero-order kinetics. Also the rate-limiting steps for one substance may be in common with other substances. For instance, the blood alcohol concentration can be used to modify the biochemistry of methanol and ethylene glycol. In this way the oxidation of methanol to the toxic formaldehyde and formic acid in the human body can be prevented by giving an appropriate amount of ethanol to a person who has ingested methanol. Methanol is very toxic and causes blindness and death. A person who has ingested ethylene glycol can be treated in the same way. Half life is also relative to the subjective metabolic rate of the individual in question.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.
NMN is a direct precursor to NAD+ in the salvage pathway. The enzyme NMNAT converts NMN into NAD+ by adding an adenine nucleotide group. This relationship is why NMN is studied in the context of NAD+ decline.
Yes, NMN is produced naturally in cells as part of NAD+ recycling. It also appears in small and variable amounts in some foods. Its natural presence does not by itself establish that supplemental NMN has clinical benefits.
Solid NMN is often stored frozen, desiccated, and protected from light. Aqueous solutions are less stable and generally require colder storage or fresh preparation.